Predicting central nervous system relapse in primary breast diffuse large B-cell lymphoma using the stage-modified...

Area of Science:

• Oncology
• Hematology
• Clinical Prognostics

Background:

• The Central Nervous System-International Prognostic Index (CNS-IPI) has limitations in predicting central nervous system (CNS) relapse for primary breast diffuse large B-cell lymphoma (DLBCL).
• Accurate prediction of CNS relapse is crucial for treatment planning and improving outcomes in DLBCL patients.

Purpose of the Study:

• To evaluate the efficacy of the stage-modified International Prognostic Index (IPI) in predicting CNS relapse in patients with primary breast DLBCL.
• To identify reliable prognostic factors for CNS relapse in this specific patient cohort.

Main Methods:

• Retrospective analysis of 76 consecutive patients diagnosed with primary breast DLBCL.
• Calculation of stage-modified IPI scores and utilization of competing risk regression (CRR) for univariate and multivariate analyses.
• Assessment of prognostic factors including stage, stage-modified IPI, and radiation therapy for CNS relapse.

Main Results:

• The cumulative incidence of CNS disease at 2 and 5 years was 3.9% and 7.8%, respectively.
• A high stage-modified IPI score (1-3 points) was significantly associated with a higher incidence of CNS relapse (p=0.031) and shorter time to relapse (p=0.010).
• Multivariate analysis identified the stage-modified IPI score (HR: 12.945, p=0.016) and radiation therapy (HR: 7.258, p=0.012) as independent predictors of CNS relapse.

Conclusions:

• The stage-modified IPI score is a significant and reliable predictor of CNS relapse in primary breast DLBCL.
• Further research is warranted to validate these findings and explore preventive strategies for CNS relapse.
• Clinical application of the stage-modified IPI may aid in risk stratification and personalized treatment for primary breast DLBCL patients.